GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenicin Inc (OTCPK:RGIN) » Definitions » Cash Ratio

Regenicin (Regenicin) Cash Ratio : 0.66 (As of Mar. 2023)


View and export this data going back to 2008. Start your Free Trial

What is Regenicin Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Regenicin's Cash Ratio for the quarter that ended in Mar. 2023 was 0.66.

Regenicin has a Cash Ratio of 0.66. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.

The historical rank and industry rank for Regenicin's Cash Ratio or its related term are showing as below:

RGIN's Cash Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 3.11
* Ranked among companies with meaningful Cash Ratio only.

Regenicin Cash Ratio Historical Data

The historical data trend for Regenicin's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenicin Cash Ratio Chart

Regenicin Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22
Cash Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Regenicin Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.67 0.66

Competitive Comparison of Regenicin's Cash Ratio

For the Biotechnology subindustry, Regenicin's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regenicin's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenicin's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Regenicin's Cash Ratio falls into.



Regenicin Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Regenicin's Cash Ratio for the fiscal year that ended in Sep. 2022 is calculated as:

Cash Ratio (A: Sep. 2022 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=0.015/5.613
=0.00

Regenicin's Cash Ratio for the quarter that ended in Mar. 2023 is calculated as:

Cash Ratio (Q: Mar. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=11.859/18.07
=0.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Regenicin  (OTCPK:RGIN) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Regenicin Cash Ratio Related Terms

Thank you for viewing the detailed overview of Regenicin's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Regenicin (Regenicin) Business Description

Traded in Other Exchanges
N/A
Address
10 High Court, Little Falls, NJ, USA, 07424
Regenicin Inc is a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs. Its skin substitute product candidate comprises of NovaDerm. NovaDerm is a multi-layered tissue-engineered living skin prepared by utilizing autologous (patient's own) skin cells. It is a graftable cultured epithelium skin substitute containing both epidermal and dermal components with a collagen base. The technology has been clinically tested in Hundreds of pediatric, catastrophic burn patients.

Regenicin (Regenicin) Headlines

No Headlines